Axial PsA and axSpA Patient Populations are Found to Have Key Similarities and Differences

A recent study presented in early June showcased how, despite some similarities, psoriatic arthritis with axial involvement (axial PsA) patients and axial spondyloarthritis (axSpA) patients have meaningful differences. These findings…

Continue Reading Axial PsA and axSpA Patient Populations are Found to Have Key Similarities and Differences
Health Canada Approves Hyrimoz for Ankylosing Spondylitis
stevepb / Pixabay

Health Canada Approves Hyrimoz for Ankylosing Spondylitis

According to GlobeNewswire, Health Canada has approved of a biosimilar, Hyrimoz, to treat ankylosing spondylitis and eight other rare conditions. Sandoz Canada is excited about this approval, as it expands…

Continue Reading Health Canada Approves Hyrimoz for Ankylosing Spondylitis
Promising New Treatments Beyond the Standards for Spondyloarthropathies
source: pixabay.com

Promising New Treatments Beyond the Standards for Spondyloarthropathies

by Lauren Taylor from In The Cloud Copy Spondyloarthropathies is an umbrella term for a group of chronic diseases that affect the joints. These can affect children and adults and…

Continue Reading Promising New Treatments Beyond the Standards for Spondyloarthropathies
Study Examines Telehealth Visits for Patients with Autoimmune Conditions During COVID-19
source: pixabay.com

Study Examines Telehealth Visits for Patients with Autoimmune Conditions During COVID-19

Michael George and his team from the University of Pennsylvania have recently uncovered new insights regarding autoimmune patient’s comfortability with care during COVID-19. They've been working since the pandemic began…

Continue Reading Study Examines Telehealth Visits for Patients with Autoimmune Conditions During COVID-19

Arthritis Treatment Shows Off-Target Benefits for Those Also Living with Diabetes

A recent study published in BMC Rheumatology has found that a combination therapy could have a benefit for individuals diagnosed with diabetes and ankylosing spondylitis (AS), psoriatic arthritis (PsA), or rheumatoid arthritis…

Continue Reading Arthritis Treatment Shows Off-Target Benefits for Those Also Living with Diabetes
Simponi Aria (Golimumab) Approved for Juvenile Arthritis Types pJIA and jPsA
https://pixabay.com/en/baby-child-cute-doll-expression-17366/

Simponi Aria (Golimumab) Approved for Juvenile Arthritis Types pJIA and jPsA

Recently, the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen") announced the FDA approval of Simponi Aria (golimumab). The therapy is designed to treat pediatric patients (ages 2 or older)…

Continue Reading Simponi Aria (Golimumab) Approved for Juvenile Arthritis Types pJIA and jPsA

Tennis Pro Caroline Wozniacki’s Advantage Hers Campaign Supports Women with Inflammatory Conditions

Caroline Wozniacki has led an interesting life. Born in Denmark, she was immediately thrust into athleticism. Her father was a former football player (that's soccer for you Americans) and her…

Continue Reading Tennis Pro Caroline Wozniacki’s Advantage Hers Campaign Supports Women with Inflammatory Conditions
Ankylosing Spondylitis Treatment Approved but Not Yet Available
https://pixabay.com/en/approved-pass-ok-approval-symbol-1726357/

Ankylosing Spondylitis Treatment Approved but Not Yet Available

According to Ankylosing Spondylitis News, a new treatment, Hulio, has been approved by the FDA. It is a treatment for ankylosing spondylitis and other inflammatory disorders. Although it has been…

Continue Reading Ankylosing Spondylitis Treatment Approved but Not Yet Available
Simponi Works for Patients with AS, RA, and PsA – Even with Prior TNF Inhibitor Treatment
mohamed_hassan / Pixabay

Simponi Works for Patients with AS, RA, and PsA – Even with Prior TNF Inhibitor Treatment

  In some cases, people have a medical condition that doesn't respond well to treatments. The journey to finding an effective treatment can be long and difficult. But for patients…

Continue Reading Simponi Works for Patients with AS, RA, and PsA – Even with Prior TNF Inhibitor Treatment

A Subcutaneous Form of Remsima May be Available Soon in the EU

Celltrion Healthcare has just announced positive progress for extending the authorization for the subcutaneous (SC) form of Remsima to five more autoimmune conditions. These are- Psoriatic arthritis Ankylosing spondylitis (AS)…

Continue Reading A Subcutaneous Form of Remsima May be Available Soon in the EU

New Lifestyle Guidelines Will Improve QOL for Patients with Rheumatic and Musculoskeletal Diseases (RMDs)

At this year's EULAR 2020 E-Congress, Dr. Suzanne Verstappen, MD, presented on how lifestyle changes could benefit patients with rheumatic and musculoskeletal diseases (RMDs). Her interest in the impact of…

Continue Reading New Lifestyle Guidelines Will Improve QOL for Patients with Rheumatic and Musculoskeletal Diseases (RMDs)
Novartis Cosentyx® Receives Positive CHMP Opinion for Non-Radiographic Axial Spondyloarthritis Treatment
source: pixabay.com

Novartis Cosentyx® Receives Positive CHMP Opinion for Non-Radiographic Axial Spondyloarthritis Treatment

  According to a press release on Global Newswire, Novartis has received a positive opinion on Cosentyx® from the Committee for Medicinal Products for Human Use (CHMP). This positive opinion…

Continue Reading Novartis Cosentyx® Receives Positive CHMP Opinion for Non-Radiographic Axial Spondyloarthritis Treatment
A Simple Blood Test Could Lead to Personalized Therapies for Rheumatoid Arthritis and Related Diseases
source: pixabay.com

A Simple Blood Test Could Lead to Personalized Therapies for Rheumatoid Arthritis and Related Diseases

A recent study led by Morten Aagaard Nielsen and Tue Wenzel Kragstrup, who both work at Aarhus University in Denmark, hopes to help physicians determine the best personalized treatment for…

Continue Reading A Simple Blood Test Could Lead to Personalized Therapies for Rheumatoid Arthritis and Related Diseases
IL-23 Inhibitors May be a Leading Treatment for Psoriasis and Psoriatic Arthritis
source: pixabay.com

IL-23 Inhibitors May be a Leading Treatment for Psoriasis and Psoriatic Arthritis

The 2019 European Academy of Dermatology and Venereology Congress was held in Madrid, Spain. During this conference, a symposium was held discussing IL-23 inhibition in psoriasis. Here are some of…

Continue Reading IL-23 Inhibitors May be a Leading Treatment for Psoriasis and Psoriatic Arthritis
The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease
source: pixabay.com

The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease

According to a story from Business Wire, the biopharmaceutical company Bristol-Myers Squibb has recently announced that the US Food and Drug Administration (FDA) has granted the company's drug abatacept (marketed…

Continue Reading The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease